HALO

Bullish

Halozyme Therapeutics Q1 2026 Earnings Review | HALO Stock - News and Statistics

Halozyme Therapeutics (NASDAQ:HALO) reported strong first-quarter 2026 results, with revenues surging 42.2% to $376.7 million, surpassing analyst expe...

IndexBox 1 week ago 0

Neutral

Vanguard Group Inc. Sells 62,890 Shares of Halozyme Therapeutics, Inc. $HALO

Vanguard Group Inc. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.5% during the fourth quarter, according to ...

tickerreport 2 weeks ago 0